Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials

Respiratory Medicine

Volumn 103, Issue 12, 2009, Pages 1960-1968

  Sears, Malcolm R ^a   Radner, Finn ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Asthma; Budesonide formoterol maintenance and reliever therapy; Safety; Serious adverse events

Indexed keywords

BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; SALBUTAMOL; TERBUTALINE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CATARACT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; GLAUCOMA; HEART DISEASE; HEART PALPITATION; HUMAN; MAINTENANCE THERAPY; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCHOOL CHILD; THRUSH; TREATMENT OUTCOME; TREMOR;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CHILD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; EPIDEMIOLOGIC METHODS; ETHANOLAMINES; FEMALE; HUMANS; MALE; MIDDLE AGED; POWDERS; YOUNG ADULT;

EID: 70350707587     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.08.007     Document Type: Article

References (30)

1. National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma: expert panel report 3 (2007), National Institutes of Health, National Heart, Lung and Blood Institute, Bethesda Publication No. 07-4051
2. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma; 2003.
3. Global Initiative for Asthma. Global strategy for asthma management and prevention - updated; 2007. www.ginasthma.com.
4. Bateman E.D., Boushey H.A., Bousquet J., Busse W.W., Clark T.J., Pauwels R.A., et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 170 8 (2004) 836-844
5. Gibson P.G., Powell H., and Ducharme F.M. Differential effects of maintenance long-acting beta-agonist and inhaled corticosteroid on asthma control and asthma exacerbations. J Allergy Clin Immunol 119 2 (2007) 344-350
6. O'Byrne P.M., Bisgaard H., Godard P.P., Pistolesi M., Palmqvist M., Zhu Y., et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 171 2 (2005) 129-136
7. Barnes P.J. Using a combination inhaler (budesonide plus formoterol) as rescue therapy improves asthma control. BMJ 335 7618 (2007) 513
8. Rabe K.F., Pizzichini E., Stallberg B., Romero S., Balanzat A.M., Atienza T., et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 129 2 (2006) 246-256
9. Scicchitano R., Aalbers R., Ukena D., Manjra A., Fouquert L., Centanni S., et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 20 9 (2004) 1403-1418
10. Bousquet J., Boulet L.P., Peters M.J., Magnussen H., Quiralte J., Martinez-Aguilar N.E., et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med 101 12 (2007) 2437-2446
11. Kuna P., Peters M.J., Manjra A.I., Jorup C., Naya I.P., Martinez-Jimenez N.E., et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 61 5 (2007) 725-736
12. Rabe K.F., Atienza T., Magyar P., Larsson P., Jorup C., and Lalloo U.G. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 368 9537 (2006) 744-753
13. Johansson G., Andreasson E.B., Larsson P.E., and Vogelmeier C.F. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics 24 7 (2006) 695-708
14. Price D., Wiren A., and Kuna P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy 62 10 (2007) 1189-1198
15. Tamminen K., Laine J., Soini E., Martikainen J., and Kankaanranta H. Cost-effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland*. Curr Med Res Opin 24 12 (2008) 3453-3461
16. Demoly P, Louis R, Søes-Petersen U, Naya I, Carlsheimer A, Worth H, Almeida J, Sears MR. Budesonide/formoterol maintenance and reliever therapy versus conventional best practice. Respir Med, in press.
17. Sears M.R., Boulet L.P., Laviolette M., FitzGerald J.M., Bai T.R., Kaplan A., et al. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. Eur Respir J 31 5 (2008) 982-989
18. Beasley R., Martinez F.D., Hackshaw A., Rabe K.F., Sterk P.J., and Djukanovic R. Safety of long-acting beta-agonists: urgent need to clear the air remains. Eur Respir J 33 1 (2009) 3-5
19. Jaeschke R., O'Byrne P.M., Mejza F., Nair P., Lesniak W., Brozek J., et al. The safety of long acting beta agonists among patients with asthma using inhaled corticosteroids. Am J Respir Crit Care Med 178 10 (2008) 1009-1016
20. Salpeter S.R., Buckley N.S., Ormiston T.M., and Salpeter E.E. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 144 12 (2006) 904-912
21. McIvor R.A., Pizzichini E., Turner M.O., Hussack P., Hargreave F.E., and Sears M.R. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 158 3 (1998) 924-930
22. Barker L., and Cadwell B.L. An analysis of eight 95 per cent confidence intervals for a ratio of Poisson parameters when events are rare. Stat Med 27 20 (2008) 4030-4037
23. Vogelmeier C., D'Urzo A., Pauwels R., Merino J.M., Jaspal M., Boutet S., et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?. Eur Respir J 26 5 (2005) 819-828
24. Nelson H.S., Weiss S.T., Bleecker E.R., Yancey S.W., and Dorinsky P.M. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129 1 (2006) 15-26
25. Sears M.R., Ottosson A., Radner F., and Suissa S. Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J 33 1 (2009) 21-32
26. Bateman E., Nelson H., Bousquet J., Kral K., Sutton L., Ortega H., et al. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med 149 1 (2008) 33-42
27. Jaeschke R., O'Byrne P.M., Nair P., Mejza F., Lesniak W., Brozek J., et al. The safety of formoterol among patients with asthma using inhaled corticosteroids. Systematic review and meta-analysis. Pol Arch Med Wewn 118 11 (2008) 627-635
28. Ni C.M., Greenstone I.R., Danish A., Magdolinos H., Masse V., Zhang X., et al. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev 4 (2005) CD005535
29. Walters E.H., Gibson P.G., Lasserson T.J., and Walters J.A. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database Syst Rev 1 (2007) CD001385
30. Barnes P.J. Scientific rationale for using a single inhaler for asthma control. Eur Respir J 29 3 (2007) 587-595